Friday, May 30, 2025

Latest

Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant

Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to find a treatment for generalized anxiety disorder. The firm this morning indicated it has begun dosing its first patients with one of its novel formulations.

The novel drug being tested under the clinical trial is referred to as MM-120, which the company classifies as a “pharmaceutically optimized” version of what is referred to as LSD. Mindmed classifies the drug as its lead candidate, with the drug having potential uses across multiple therapeutic areas in addition to generalized anxiety disorder, such as psychiatry, pain, and substance use disorders.

The current study looks to determine if a reduction in anxiety symptoms is present four weeks after a single dose of the drug, with secondary objectives such as assessments of quality of life, safety, and tolerability to be measured after twelve weeks.

“The initiation of our Phase 2b clinical trial, the largest well-controlled clinical trial of LSD ever conducted, represents a major milestone for MindMed and for the many patients suffering from GAD. This exciting next step in the advancement of LSD builds on the positive topline data presented by our partners at University Hospital Basel in May 2022, which demonstrated the rapid, durable, and statistically significant effects of LSD and its potential to safely mitigate symptoms of anxiety and depression,” stated CEO Robert Barrow.

The trial itself is set to be conducted on a total of 200 patients, with dosages of MM-120 ranging to upwards of 200 µg to be delivered to patients on a randomized basis, or placebo. The study is also looking to identify dose optimization for further trials, with the trial to guide dose selection and development of the Phase 3 trials for the drug.

The development follows the firm earlier this month filing its second quarter financial results, which were highlighted by a cash position of US$105.7 million.

Mind Medicine last traded at $1.14 on the Neo.


Information for this briefing was found via Edgar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

First Majestic Makes Second Major Discovery At Santa Elena In Just A Year

Related News

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to...

Wednesday, June 9, 2021, 07:50:06 AM

Mind Medicine Applies To List On The Nasdaq

Mind Medicine (NEO: MMED) this morning announced that it has submitted an application to uplist...

Monday, September 21, 2020, 07:53:31 AM

Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan...

Tuesday, December 21, 2021, 08:22:51 AM

MindMed Sees Positive Results For Its LSD Treatment For Anxiety Disorders Published In Peer-Reviewed Journal

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday that the...

Thursday, September 8, 2022, 05:03:00 PM

Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements

In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that...

Friday, August 5, 2022, 08:42:02 AM